abs73.txt	background		differential	use	of	endocrine	therapy	(et)	by	race	may	contribute	tobreast	cancer	outcome	disparities		but	racial	differences	in	et	behaviors	arepoorly	understood	methods		women	aged	20-74	years	with	a	first	primary		stage	i-iii		hormonereceptor-positive	(hr+)	breast	cancer	were	included		at	2	years	postdiagnosis		weassessed	nonadherence		defined	as	not	taking	et	every	day	or	missing	more	thantwo	pills	in	the	past	14	days		discontinuation		and	a	composite	measure	ofunderuse		defined	as	either	missing	pills	or	discontinuing	completely		usinglogistic	regression		we	evaluated	the	relationship	between	race	and	nonadherence	discontinuation		and	overall	underuse	in	unadjusted		clinically	adjusted		andsocioeconomically	adjusted	models	results		a	total	of	1280	women	were	included		43	2%	self-identified	as	black	compared	to	white	women		black	women	more	often	reported	nonadherence	(13	7%	vs5	2%)	but	not	discontinuation	(10	0%	vs	10	7%)		black	women	also	more	oftenreported	the	following		hot	flashes		night	sweats		breast	sensitivity		and	jointpain		believing	that	their	recurrence	risk	would	not	change	if	they	stopped	et	forgetting	to	take	et		and	cost-related	barriers		in	multivariable	analysis	black	race	remained	statistically	significantly	associated	with	nonadherenceafter	adjusting	for	clinical	characteristics	(adjusted	odds	ratio	=	2	72		95%confidence	interval	=	1	75	to	4	24)	and	after	adding	socioeconomic	to	clinicalcharacteristics	(adjusted	odds	ratio	=	2	44		95%	confidence	interval	=	1	50	to3	97)	but	was	not	independently	associated	with	discontinuation	after	adjustment	low	recurrence	risk	perception	and	lack	of	a	shared	decision	making	were	stronglypredictive	of	et	underuse	across	races	conclusions		our	results	highlight	important	racial	differences	in	et-adherencebehaviors		perceptions	of	benefits/harms		and	shared	decision	making	that	may	betargeted	with	culturally	tailored	interventions	
